NO20080552L - GLP-1 farmasoytiske sammensetninger - Google Patents

GLP-1 farmasoytiske sammensetninger

Info

Publication number
NO20080552L
NO20080552L NO20080552A NO20080552A NO20080552L NO 20080552 L NO20080552 L NO 20080552L NO 20080552 A NO20080552 A NO 20080552A NO 20080552 A NO20080552 A NO 20080552A NO 20080552 L NO20080552 L NO 20080552L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
glp
analogues
peptide
glucagon
Prior art date
Application number
NO20080552A
Other languages
English (en)
Norwegian (no)
Inventor
Zheng Xin Dong
Roland Cherif-Cheikh
Frederic Lacombe
Jose-Antonio Cordero Rigol
Resurreccion Alloza Miravete
Maria Dolores Tobalina Maestre
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20080552L publication Critical patent/NO20080552L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20080552A 2005-06-30 2008-01-30 GLP-1 farmasoytiske sammensetninger NO20080552L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69614205P 2005-06-30 2005-06-30
PCT/US2006/025826 WO2007005738A2 (en) 2005-06-30 2006-06-30 Glp-1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20080552L true NO20080552L (no) 2008-03-27

Family

ID=37605098

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080552A NO20080552L (no) 2005-06-30 2008-01-30 GLP-1 farmasoytiske sammensetninger

Country Status (13)

Country Link
US (2) US8236759B2 (de)
EP (2) EP2441460A1 (de)
KR (1) KR20080028981A (de)
CN (1) CN101258163B (de)
AR (1) AR055346A1 (de)
AU (1) AU2006265814B2 (de)
CA (1) CA2617859A1 (de)
EA (1) EA012287B1 (de)
MX (1) MX2008001468A (de)
NO (1) NO20080552L (de)
NZ (1) NZ565535A (de)
TW (1) TWI364292B (de)
WO (1) WO2007005738A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008082656A1 (en) * 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2687918C (en) * 2007-06-08 2016-11-08 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CL2008001671A1 (es) * 2007-06-08 2009-07-17 Janssen Pharmaceutica Nv Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes.
EP2296659B1 (de) 2008-06-05 2016-12-21 Janssen Pharmaceutica, N.V. Einen DGAT-Inhibitor und einen PPAR-Agonisten enthaltende Arzneikombinationen
EP2216042A1 (de) * 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP1-analoge pharmazeutische Zusammensetzungen
CN106999553B (zh) * 2014-05-07 2021-11-26 诺和诺德股份有限公司 使用glp-1和抗-il-21对1型糖尿病的治疗

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591496A (en) * 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (de) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-ähnliche, insalinotrope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren
DE69508985T2 (de) * 1994-02-21 1999-08-19 Takeda Chemical Industries Ltd Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69904701T2 (de) 1998-03-20 2003-11-06 Takeda Chemical Industries Ltd Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
EP1100530B1 (de) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
ES2227115T5 (es) 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001228327A1 (en) 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
CA2402733A1 (en) 2000-03-14 2001-09-20 Burkhard Goke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
KR100518046B1 (ko) 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
HU229208B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002016430A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University Peptide with effects on cerebral health
ATE470448T1 (de) 2000-10-20 2010-06-15 Amylin Pharmaceuticals Inc Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
CN1501809B (zh) 2000-12-13 2012-10-10 伊莱利利公司 应用胰高血糖素样促胰岛肽的长期治疗方案
WO2002048192A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
SK1432004A3 (sk) 2001-10-01 2005-03-04 Eli Lilly And Company Liečivo na znižovanie mortality a morbidity súvisiacich s kritickými ochoreniami
JP2005506074A (ja) 2001-10-18 2005-03-03 イクシオン・バイオテクノロジー・インコーポレーテッド 肝臓の幹細胞および前駆細胞の膵臓機能細胞への転換
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
JP2007514752A (ja) 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EP2409707B8 (de) * 2004-04-15 2015-05-06 Alkermes Pharma Ireland Limited Vorrichtung auf Polymerbasis mit verzögerter Freisetzung
PL1750683T3 (pl) * 2004-04-23 2013-05-31 Amgen Inc Formuły o przedłużonym uwalnianiu
JP5000493B2 (ja) * 2004-05-20 2012-08-15 ディアメディカ インコーポレイテッド インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット

Also Published As

Publication number Publication date
NZ565535A (en) 2011-03-31
MX2008001468A (es) 2008-04-07
EP2441460A1 (de) 2012-04-18
KR20080028981A (ko) 2008-04-02
US20120277151A1 (en) 2012-11-01
WO2007005738A3 (en) 2007-09-13
TWI364292B (en) 2012-05-21
CA2617859A1 (en) 2007-01-11
TW200740456A (en) 2007-11-01
EA200800181A1 (ru) 2008-06-30
AU2006265814B2 (en) 2012-05-10
CN101258163A (zh) 2008-09-03
US8236759B2 (en) 2012-08-07
AU2006265814A1 (en) 2007-01-11
WO2007005738A2 (en) 2007-01-11
AR055346A1 (es) 2007-08-22
EP1904525A4 (de) 2009-10-21
EA012287B1 (ru) 2009-08-28
US20070021339A1 (en) 2007-01-25
CN101258163B (zh) 2013-08-21
EP1904525A2 (de) 2008-04-02

Similar Documents

Publication Publication Date Title
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
NO20100307L (no) GLP-1 analoger
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
UA114710C2 (uk) Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить
EA201000399A1 (ru) Композиции и способы использования проостровковых пептидов и их аналогов
MX2009002666A (es) Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos.
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
EA200802058A1 (ru) Производные циклоалкиламинокислот и их фармацевтические композиции
ATE522226T1 (de) Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms
HK1088840A1 (en) Stable analogs of glp-1 glp-1
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
WO2004074315A3 (en) Analogues of glp-1
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EA200900373A1 (ru) Реконструированные сурфактанты, обладающие улучшенными свойствами
CY1119819T1 (el) Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας
EP2510941A3 (de) Verfahren zur Behandlung von multipler Sklerose mittels Verabreichung eines alpha-Fetoproteins in Kombination mit einem Integrinantagonisten
TR201900959T4 (tr) Bi̇leşi̇mler ve bunlarin tibbi̇ kullanimi.
EP2210900A3 (de) GlLP-1-Analoga

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application